Table 1.

Baseline patient characteristics

	Dose escalation	Dose expansion
Number of patients	15	18
Median Age, years (range)	60 (41-73)	55 (27-89)
Gender, n (%)
Male	9 (60)	15 (83)
Female	6 (40)	3 (17)
Race, n (%)
Caucasian	15 (100)	16 (89)
African-American	0	2 (11)
ECOG PS, n (%)
0	7 (47)	3 (17)
1	8(53)	15 (83)
Primary Tumor Type, n (%)
Colorectal Cancer	11 (73)	18 (100)
Non Small Cell Lung Cancer	2 (13)	0 (0)
Head and Neck Cancer	2 (13)	0 (0)
Prior Systemic Therapy
Mean number of regimens (range)	4.7 (1-8)	2.8 (2-4)
KRAS Mutation Status, n (%)
Mutant	8 (53)	18 (100)
Wild-type	2 (13)	0 (0)
Unknown	5 (34)	0 (0)
Prior EGFR-directed Therapy, n (%)	5 (33)	2 (11)